Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current HIV/AIDS Reports

• Publication date

  2016-08-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11904-016-0331-yPMID 27562769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Behavioral Interventions for Tobacco Use in HIV-Infected Smokers: A Meta-Analysis

  2016cited by this paper
• Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV

  2016cited by this paper
• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

  2016cited by this paper
• Trends in Cardiovascular Disease Mortality Among Persons With HIV in New York City, 2001-2012.

  2016cited by this paper
• First generation versus second generation drug‐eluting stents for the treatment of bifurcations: 5‐year follow‐up of the LEADERS all‐comers randomized trial

  2016cited by this paper
• Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals

  2016cited by this paper
• Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

  2015cited by this paper
• RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.

  2015cited by this paper
• Evaluating patterns in retention, continuation, gaps, and re-engagement in HIV care in a Medicaid-insured population, 2006–2012, United States

  2015cited by this paper
• Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

  2015cited by this paper
• Chemokine Coreceptor-2 Gene Polymorphisms among HIV-1 Infected Individuals in Kenya

  2015cited by this paper
• Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial

  2015cited by this paper
• HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis.

  2015cited by this paper
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

  2015cited by this paper
• A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

  2015cited by this paper
• A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness

  2015influential reference
• Site-Specific Differences in T Cell Frequencies and Phenotypes in the Blood and Gut of HIV-Uninfected and ART-Treated HIV+ Adults

  2015cited by this paper
• Prevalence of Diagnosed and Undiagnosed HIV Infection - United States, 2008–2012

  2015cited by this paper
• Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy

  2015influential reference
• Sleeve Gastrectomy Is a Safe and Efficient Procedure in HIV Patients with Morbid Obesity: a Case Series with Results in Weight Loss, Comorbidity Evolution, CD4 Count, and Viral Load

  2015cited by this paper
• Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV

  2015cited by this paper
• Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.

  2015cited by this paper
• Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.

  2015influential reference
• Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice

  2015cited by this paper
• Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey

  2015cited by this paper
• Cigarette Smoking Prevalence Among Adults With HIV Compared With the General Adult Population in the United States

  2015influential reference
• Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the “Probio-HIV” Clinical Trial

  2015cited by this paper
• Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

  2015cited by this paper
• Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy

  2015cited by this paper
• HIV and the Gut Microbiota, Partners in Crime: Breaking the Vicious Cycle to Unearth New Therapeutic Targets

  2015cited by this paper
• Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.

  2014cited by this paper
• 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque

  2014cited by this paper
• Higher rates of metabolic syndrome among women taking zidovudine as compared to tenofovir in rural Africa: preliminary data from the CART-1 study

  2014cited by this paper
• Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

  2014influential reference
• Immunodeficiency and Risk of Myocardial Infarction Among HIV-Positive Individuals With Access to Care

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.

  2014cited by this paper
• Beneficial impact of antiretroviral therapy on non-AIDS mortality.

  2014cited by this paper
• Reduction of HIV Persistence Following Transplantation in HIV‐Infected Kidney Transplant Recipients

  2014cited by this paper
• Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study

  2014cited by this paper
• Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation

  2014cited by this paper
• Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

  2014cited by this paper
• HIV infection and incidence of ischemic stroke

  2014cited by this paper
• Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

  2014cited by this paper
• Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study

  2014cited by this paper
• Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection

  2014cited by this paper
• Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV‐positive individuals

  2014cited by this paper
• Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals

  2014cited by this paper
• Evidence for innate immune system activation in HIV type 1-infected elite controllers.

  2014cited by this paper
• Will statins be an effective anti-inflammatory intervention for prevention of cardiovascular disease in patients with HIV?

  2014cited by this paper
• Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

  2014cited by this paper
• CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV.

  2013cited by this paper
• Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

  2013cited by this paper
• Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

  2013cited by this paper
• Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

  2013cited by this paper
• Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.

  2013cited by this paper
• Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy: A Pilot Study

  2013cited by this paper
• Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study.

  2013cited by this paper
• A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial

  2013cited by this paper
• HIV infection and the risk of acute myocardial infarction.

  2013cited by this paper
• HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals.

  2012cited by this paper
• Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals

  2012cited by this paper
• Arterial inflammation in patients with HIV.

  2012cited by this paper
• No Association of Abacavir Use With Myocardial Infarction: Findings of an FDA Meta-Analysis

  2012cited by this paper
• Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

  2012cited by this paper
• Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.

  2012cited by this paper
• Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals.

  2012cited by this paper
• Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation

  2012cited by this paper
• HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.

  2012cited by this paper
• Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

  2012cited by this paper
• Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy: The Swiss HIV Cohort Study

  2012cited by this paper
• A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis

  2012cited by this paper
• Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort

  2012cited by this paper
• Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

  2011cited by this paper
• Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care

  2011cited by this paper
• Plasma levels of soluble CD14 independently predict mortality in HIV infection.

  2011cited by this paper
• Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data

  2011cited by this paper
• Prevalence and Prognostic Significance of ECG Abnormalities in HIV-infected Patients: Results from the Strategies for Management of Antiretroviral Therapy (SMART) Study

  2011cited by this paper
• No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

  2011cited by this paper
• The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.

  2011cited by this paper
• Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.

  2011cited by this paper
• Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study

  2011cited by this paper
• Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

  2011cited by this paper
• Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

  2011cited by this paper
• Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals

  2011cited by this paper
• The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy *

  2011cited by this paper
• Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons

  2011cited by this paper
• Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.

  2010cited by this paper
• Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study

  2010cited by this paper
• Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

  2010cited by this paper
• Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation

  2010cited by this paper
• Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

  2010cited by this paper
• Impact of atazanavir-based HAART regimen on the carotid intima–media thickness of HIV-infected persons: a comparative prospective cohort

  2010cited by this paper
• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

  2010cited by this paper
• Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort

  2010cited by this paper
• Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

  2010influential reference
• Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

  2010cited by this paper
• Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.

  2010cited by this paper
• HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction

  2009cited by this paper
• HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies

  2009cited by this paper

• A review on the disease risk and contemporary management of PAD in the HIV population.

  2025cites this paper
• Atherogenic Index of Plasma and High-Sensitivity C-Reactive Protein Levels Among People Living With HIV on Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy and Their Correlations to CD4 Cell Counts

  2025cites this paper
• HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps

  2024cites this paper
• Serum uric acid and high-sensitivity C-reactive protein levels among people living with HIV on dolutegravir and ritonavir-boosted atazanavir-based antiretroviral therapy: a comparative cross-sectional study

  2024cites this paper
• Complicaciones no infecciosas del paciente con infección por el virus de la inmunodeficiencia humana

  2022cites this paper
• Assessment of the comorbidity index in HIV-infected patients before ART

  2022cites this paper
• Hypertension and human immunodeficiency virus: A paradigm for epithelial sodium channels?

  2022cites this paper
• Coronary artery aneurysm, ectasia and stenosis in a 53-year-old man with HIV infection

  2022cites this paper
• Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation

  2021cites this paper
• Weight Gain and Related Comorbidities Following Antiretroviral Initiation in the 2000s: A Systematic Literature Review

  2021cites this paper
• Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.

  2020cites this paper
• Assessing inflammation and its role in comorbidities among persons living with HIV

  2019cites this paper
• HIV-associated cardiovascular pathology

  2019cites this paper
• The Changing Face of HIV

  2019cites this paper
• Senescent Phenotype Induced by p90RSK-NRF2 Signaling Sensitizes Monocytes and Macrophages to Oxidative Stress in HIV-Positive Individuals: Implications for Atherogenesis

  2019cites this paper
• A time‐motion study of cardiovascular disease risk factor screening integrated into HIV clinic visits in Swaziland

  2018cites this paper
• Food security and dietary diversity are associated with health related quality of life after 6 months of follow up among people living with HIV in Accra, Ghana

  2018cites this paper
• Effect of a Structured Pharmaceutical Care Intervention Versus Usual Care on Cardiovascular Risk in HIV Patients on Antiretroviral Therapy: INFAMERICA Study

  2018cites this paper
• JCL roundtable: Managing lipid disorders in patients with HIV.

  2017cites this paper
• Factors affecting affect cardiovascular health in Indonesian HIV patients beginning ART

  2017cites this paper